During the World Economic Forum Annual Meeting 2026 (the "Winter Davos Forum"), Sino Biopharm's (1177.HK) active M&A transactions and globalized innovation strategy attracted attention from numerous media outlets at home and abroad. In interviews with media outlets such as Xinhua News Agency, CGTN, and Bloomberg, the Chief Executive Officer of Sino Biopharm and Chairman of Chia Tai Tianqing stated that at this critical juncture where Chinese pharmaceutical innovation is accelerating its global expansion, Sino Biopharm will enhance medicine accessibility through further open cooperation, allowing more patients in more countries and regions to share the fruits of innovation. 

In an interview with Bloomberg, Mr. Eric Tse described the past year as the inaugural year for the company to systematically launch mergers and acquisitions as a major pharmaceutical enterprise. In 2025, Sino Biopharm's full acquisition of LaNova Medicines was seen at home and abroad as a landmark case of a domestic Big Pharma proactively integrating a top-tier domestic Biotech. The acquisition of Hygieia at the beginning of 2026 further reflects the determination of large Chinese pharmaceutical companies to accelerate their transformation into world-class pharmaceutical enterprises by integrating global innovation resources. "Every investment and acquisition is carefully considered and part of a systematic layout focused on long-term technological capabilities", said Mr. Eric Tse, adding that the company currently has over 200 potential projects under evaluation. 

While advancing existing transactions, Sino Biopharm is also actively seeking more cooperation opportunities. Regarding its rich and high-quality pipelines, the company is in close communication with several multinational corporations (MNCs). Mr. Eric Tse noted, "We are not only focused on out-licensing; we may also cooperate with funds to advance overseas clinical trials, or even advance them independently. The development paths for different drugs vary greatly". The relatively abundant cash reserves provide the company with ample strategic flexibility. Sino Biopharm will continue to focus on four core therapeutic areas, and enhance its international influence through mergers and acquisitions, licensing collaborations, and partnerships. 

In the past year, the rapid rise of Chinese pharmaceutical innovation has attracted global attention. The proportion of global clinical trials involving China has increased to nearly one-third, and the value of overseas licensing for innovative drugs has reached 130 billion US dollars. Mr. Eric Tse believes this change stems from the talent dividend accumulated over many years, government policy support for innovation, and the practical demands of the Chinese market for speed and cost. These factors have prompted Chinese pharmaceutical companies to gradually form an innovation system that balances both quality and efficiency, a system that is now gaining international recognition. 

In an interview with CGTN, Mr. Eric Tse stated that China's contribution to global health is not only reflected in individual drugs or specific technologies but more importantly in the industrial infrastructure and innovation ecosystem it has built. As biopharmaceutical industrial clusters accelerate their formation in places like Shanghai, Beijing, Guangzhou, and Jiangsu, China is providing treatment solutions to the world in a more accessible and affordable manner. 

However, a set of figures from the World Economic Forum indicated that 4.5 billion people globally still lack access to basic healthcare services in the public health sector. The forum called for enhanced collaboration among governments, enterprises, and society to find common solutions. In Mr. Eric Tse's view, "Pharmaceutical innovation transcends national borders".  Developing countries, especially some countries and regions in the Asia-Pacific area and along the "Belt and Road", still have huge unmet medical needs. China has close ethnic and geographical ties with these countries and can accelerate the simultaneous review and launch of innovative drugs by promoting regional mutual recognition of clinical data, allowing good Chinese medicines to benefit more patients. 

Disclaimer:
The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited. 

Source: Xinhua News Agency, CGTN, Bloomberg